S.V. Osipova

S.V. Osipova

Auto-generated profile, based on publicly available information

S.V. Osipova

Sechenov First Moscow State Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Doctor.Ru
Verified
Journal Article
Open access
BHBotkin Hospital
Botkin Hospital
PDP.A. Drozdov
P.A. Drozdov
RMRussian Federation Moscow
Russian Federation Moscow
RMRussian Federation Russian Medical Academy Of Continuous Professional Education; Moscow
Russian Federation Russian Medical Academy Of Continuous Professional Education; Moscow
AAA.S. Ametov
A.S. Ametov
NIN.A. Ivanova
N.A. Ivanova
Aim. To demonstrate a case of severe hepatic encephalopathy with focal neurological symptoms in the early postoperative period after transjugular intrahepatic portosystemic shunting (TIPS). Key points. TIPS is the most common and effective pathogenetically justified shunting method for correcting portal hypertension in liver cirrhosis. The modern transplantology doctrine dictates an increasing need for TIPS as a bridge technology that improves patient survival on the liver transplant waiting list. The progression of hepatic encephalopathy in the postoperative period following this intervention is the main expected adverse consequence of the procedure. Timely diagnosis of worsening neuropsychiatric function in patients who have undergone TIPS and its effective restoration are pressing issues in contemporary gastroenterological practice. Screening examinations to detect hepatic encephalopathy should be regularly performed for all patients, who have undergone TIPS, regardless of the timing of the procedure. Complex therapy, including ornithine, lactulose, and antibacterial drugs to suppress excessive bacterial growth in the intestine, should be prescribed from the first days after the intervention. Since suppressing excessive bacterial growth in the intestine in patients with hepatic encephalopathy is an independent pathogenetically based therapeutic target, cyclical use of antibacterial agents for intestinal sanitation in patients with TIPS significantly enhances the effectiveness of controlling hepatic encephalopathy. Conclusion. This case clearly demonstrates that the foundation of successful treatment for a patient with liver cirrhosis lies in the continuity and interconnection of all stages of care provision. Keywords: hepatic encephalopathy, transjugular intrahepatic portosystemic shunt, TIPS, portal hypertension, liver cirrhosis, liver transplant waiting list, excessive bacterial growth, cyclical bowel sanitation

17 December 2024 in Russian Journal of Evidence-Based Gastroenterology
Verified
Journal Article
Closed access
Vladislav AvdyshevVladislav Avdyshev
Vladislav Avdyshev
AKA.A. Kharlamova
A.A. Kharlamova
AKA.E. Kucher
A.E. Kucher
VSVladislav Sergeevich Skossyrskiy
Vladislav Sergeevich Skossyrskiy
SOS.V. Osipova
S.V. Osipova
CPChavdar Pavlov
Chavdar Pavlov
Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease that can lead to cirrhosis and its complications. The lack of strict diagnostic criteria for AIH complicates diagnosis and delays the initiation of appropriate therapy. Treatment selection and patient management remain challenges. Objective. To highlight the diagnostic and therapeutic aspects of AIH based on a clinical case. Clinical case. A 33-year-old female presented with significant cytolysis and cholestasis. A differential diagnosis ruled out viral hepatitis, liver storage diseases, and drug-induced liver injury (the patient had taken paracetamol and amoxicillin-clavulanate for a recent viral infection). Anti-SLA/LP antibodies were detected, while ANA, AMA, ANCA, SMA, and anti-LKM were within reference ranges. A liver biopsy revealed features of AIH and grade 1 steatosis. The final diagnosis was chronic AIH with high cytolytic activity, intrahepatic cholestasis, and parenchymal jaundice. Immunosuppressive therapy with prednisolone (40 mg/day) and azathioprine (50 mg/day) was initiated, with dosage adjustments for side effects. Despite four years of therapy, full biochemical and morphological remission was not achieved, and the risk of cirrhosis remains. This case underscores the challenges of diagnosing AIH and its potential overlap with cholestatic liver diseases. The article also discusses the need to monitor therapy-related side effects and the role of thiopurine S-methyltransferase testing in treatment. Conclusion. The heterogeneity of AIH symptoms complicates early diagnosis. A comprehensive approach, including autoantibody testing and imaging, is essential for timely and accurate diagnosis.